Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The objective are to assess the nature and incidence of drug intolerance observed with a new
antiretroviral triple therapy, Truvada® [0-0-1] + Isentress® 400 mg tablets [1-0-1],
prescribed in a setting of the treatment of individuals with recent exposure to a risk of
transmission of HIV infection and to compare the results with those of previous studies
conducted according to the same methodology, with other combinations of antiretrovirals.
Phase:
Phase 3
Details
Lead Sponsor:
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium